Global T-cell lymphoma Market 2022-2026

Description

List of Tables

Technavio has been monitoring the T-cell lymphoma market and it is poised to grow by $ 768.07 mn during 2022-2026, accelerating at a CAGR of 8.21% during the forecast period. Our report on the T-cell lymphoma market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing geriatric population, increasing approval of therapeutics for patients with relapsed or refractory T-cell lymphoma, and increasing incidence of T-cell lymphoma.

The T-cell lymphoma market analysis includes the type segment and geographic landscape.

Technavio's T-cell lymphoma market is segmented as below:

By Type

Peripheral T-cell lymphomas
T-cell lymphoblastic lymphoma

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies technological advancements as one of the prime reasons driving the T-cell lymphoma market growth during the next few years. Also, increasing patient support programs and strategic alliances will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the T-cell lymphoma market covers the following areas:

T-cell lymphoma market sizing
T-cell lymphoma market forecast
T-cell lymphoma market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading T-cell lymphoma market vendors that include AbbVie Inc., Accredo Health Group Inc., AstraZeneca Plc, Autolus Therapeutics Plc, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Genmab AS, GSK Plc, H. Lee Moffitt Cancer Center and Research Institute Inc., Johnson and Johnson, Macopharma SA, Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and TYME Inc. Also, the T-cell lymphoma market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Product Code: IRTNTR74125

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

5.1 Market segments
Exhibit 24: Chart on Type - Market share 2021-2026 (%)
Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
5.2 Comparison by Type
Exhibit 26: Chart on Comparison by Type
Exhibit 27: Data Table on Comparison by Type
5.3 Peripheral T-cell lymphomas - Market size and forecast 2021-2026
Exhibit 28: Chart on Peripheral T-cell lymphomas - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Peripheral T-cell lymphomas - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Peripheral T-cell lymphomas - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Peripheral T-cell lymphomas - Year-over-year growth 2021-2026 (%)
5.4 T-cell lymphoblastic lymphoma - Market size and forecast 2021-2026
Exhibit 32: Chart on T-cell lymphoblastic lymphoma - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on T-cell lymphoblastic lymphoma - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on T-cell lymphoblastic lymphoma - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on T-cell lymphoblastic lymphoma - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Type
Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

6.1 Customer landscape overview
Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

7.1 Geographic segmentation
Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 40: Chart on Geographic comparison
Exhibit 41: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Germany - Market size and forecast 2021-2026
Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.9 UK - Market size and forecast 2021-2026
Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
7.10 Canada - Market size and forecast 2021-2026
Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.11 China - Market size and forecast 2021-2026
Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)
7.12 Market opportunity By Geographical Landscape
Exhibit 78: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 79: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends

9 Vendor Landscape

9.1 Overview
9.2 Vendor landscape
Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 81: Overview on factors of disruption
9.4 Industry risks
Exhibit 82: Impact of key risks on business

10 Vendor Analysis

10.1 Vendors covered
Exhibit 83: Vendors covered
10.2 Market positioning of vendors
Exhibit 84: Matrix on vendor position and classification
10.3 AbbVie Inc.
Exhibit 85: AbbVie Inc. - Overview
Exhibit 86: AbbVie Inc. - Product / Service
Exhibit 87: AbbVie Inc. - Key offerings
10.4 AstraZeneca Plc
Exhibit 88: AstraZeneca Plc - Overview
Exhibit 89: AstraZeneca Plc - Product / Service
Exhibit 90: AstraZeneca Plc - Key news
Exhibit 91: AstraZeneca Plc - Key offerings
10.5 Biogen Inc.
Exhibit 92: Biogen Inc. - Overview
Exhibit 93: Biogen Inc. - Product / Service
Exhibit 94: Biogen Inc. - Key offerings
10.6 Bristol Myers Squibb Co.
Exhibit 95: Bristol Myers Squibb Co. - Overview
Exhibit 96: Bristol Myers Squibb Co. - Product / Service
Exhibit 97: Bristol Myers Squibb Co. - Key offerings
10.7 F. Hoffmann La Roche Ltd.
Exhibit 98: F. Hoffmann La Roche Ltd. - Overview
Exhibit 99: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 100: F. Hoffmann La Roche Ltd. - Key news
Exhibit 101: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 102: F. Hoffmann La Roche Ltd. - Segment focus
10.8 GSK Plc
Exhibit 103: GSK Plc - Overview
Exhibit 104: GSK Plc - Business segments
Exhibit 105: GSK Plc - Key news
Exhibit 106: GSK Plc - Key offerings
Exhibit 107: GSK Plc - Segment focus
10.9 Johnson and Johnson
Exhibit 108: Johnson and Johnson - Overview
Exhibit 109: Johnson and Johnson - Business segments
Exhibit 110: Johnson and Johnson - Key news
Exhibit 111: Johnson and Johnson - Key offerings
Exhibit 112: Johnson and Johnson - Segment focus
10.10 Merck and Co. Inc.
Exhibit 113: Merck and Co. Inc. - Overview
Exhibit 114: Merck and Co. Inc. - Business segments
Exhibit 115: Merck and Co. Inc. - Key news
Exhibit 116: Merck and Co. Inc. - Key offerings
Exhibit 117: Merck and Co. Inc. - Segment focus
10.11 Novartis AG
Exhibit 118: Novartis AG - Overview
Exhibit 119: Novartis AG - Business segments
Exhibit 120: Novartis AG - Key offerings
Exhibit 121: Novartis AG - Segment focus
10.12 Pfizer Inc.
Exhibit 122: Pfizer Inc. - Overview
Exhibit 123: Pfizer Inc. - Product / Service
Exhibit 124: Pfizer Inc. - Key news
Exhibit 125: Pfizer Inc. - Key offerings

11 Appendix

11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 126: Inclusions checklist
Exhibit 127: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 128: Currency conversion rates for US$
11.4 Research methodology
Exhibit 129: Research methodology
Exhibit 130: Validation techniques employed for market sizing
Exhibit 131: Information sources
11.5 List of abbreviations
Exhibit 132: List of abbreviations